Allorion Therapeutics Employee Directory
Pharmaceutical ManufacturingMassachusetts, United States11-50 Employees
Allorion Therapeutics is a pharmaceutical company that focuses on discovering and developing novel small molecule drugs for cancer and autoimmune diseases, supported by a team with expertise in cancer biology and drug development. The company operates dual sites in Natick, Massachusetts and Guangzhou, China, and maintains a workforce of 11 to 50 employees. Its research priorities include selecting well-validated targets with clear clinical development routes, discovering modulators with distinct mechanisms of action, advancing data and screening platforms, and constructing chemical libraries that emphasize allosteric and covalent modulators with AI-assisted optimization. Allorion has engaged in strategic collaborations, including an exclusive option and global license agreement with AstraZeneca to develop an allosteric EGFR L858R inhibitor for NSCLC, and it completed a Series B financing in 2023. Recent information indicates that Allorion sold assets to Avenzo Therapeutics on June 1, 2026.